Dr. Susan Schneider joins Santen as VP, clinical affairs

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co. Ltd., announced that Susan Schneider, MD, has joined the company as vice president of clinical affairs.

Dr. Schneider will be responsible for developing and implementing all clinical development strategies for Santen Inc., including being involved with the company's strategies for research and development; approving methods for designing, monitoring, and reporting of clinical trials in the United States; monitoring adherence to protocols; and staying abreast of current developments in clinical research.

In her previous role as medical director for Genentech Inc., Dr. Schneider was responsible for monitoring clinical trials, publication strategy and execution, filings, and research. She worked as medical monitor and clinical trials director for the company's products, including ranibizumab (Lucentis), which was approved by the FDA in 2006.

For more information, visit Santen at Booth 711.